Abstract : By use of a murine model for Buruli ulcer, Mycobacterium ulcerans was found to be susceptible to rifampin, with the MIC being 0.5 to 1 micro g/ml. Three mutants were isolated after rifampin monotherapy. Two were resistant to rifampin at 8 micro g/ml, and one was resistant to rifampin at 32 micro g/ml. The mutants harbored Ser416Phe mutations and His420Tyr mutations in the rpoB gene, and these mutations have also been found to be responsible for rifampin resistance in the leprosy and tubercle bacilli. The results indicate that while rifampin may be active against M. ulcerans, it should never be used as monotherapy in humans.
https://www.hal.inserm.fr/inserm-03400832 Contributor : laurent MarsollierConnect in order to contact the contributor Submitted on : Monday, October 25, 2021 - 10:51:29 AM Last modification on : Thursday, April 7, 2022 - 10:10:26 AM Long-term archiving on: : Wednesday, January 26, 2022 - 7:06:24 PM
File
Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed
until : jamais
Laurent C Marsollier, Nadine Honore, Pierre Legras, Anne-Lise Manceau, Henri Kouakou, et al.. Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2003, 47 (4), pp.1228-1232. ⟨10.1128/AAC.47.4.1228-1232.2003⟩. ⟨inserm-03400832⟩